EA200401100A1 - 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ - Google Patents

1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ

Info

Publication number
EA200401100A1
EA200401100A1 EA200401100A EA200401100A EA200401100A1 EA 200401100 A1 EA200401100 A1 EA 200401100A1 EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A1 EA200401100 A1 EA 200401100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bishomo
hydroxy
treatment
spherol
epicholocalti
Prior art date
Application number
EA200401100A
Other languages
English (en)
Other versions
EA010240B1 (ru
Inventor
Лучано Адорини
Энрико Колли
Original Assignee
Биокселл Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Биокселл Спа filed Critical Биокселл Спа
Publication of EA200401100A1 publication Critical patent/EA200401100A1/ru
Publication of EA010240B1 publication Critical patent/EA010240B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Применение 1α-фтор-25-гидрокси-16,23E-диен-26,27-бисгомо-20-эпихолекальциферола, или его фармацевтически приемлемой соли, или сложного эфира для получения лекарственного средства, предназначенного для профилактики и/или лечения доброкачественной гиперплазии предстательной железы (BPH) и ассоциированных симптомов.
EA200401100A 2003-09-24 2004-09-23 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ EA010240B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
EA200401100A1 true EA200401100A1 (ru) 2005-04-28
EA010240B1 EA010240B1 (ru) 2008-06-30

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401100A EA010240B1 (ru) 2003-09-24 2004-09-23 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ

Country Status (11)

Country Link
EP (1) EP1673096A1 (ru)
JP (2) JP2007506699A (ru)
CN (1) CN100488511C (ru)
BE (1) BE1016292A3 (ru)
BR (1) BRPI0404050A (ru)
CH (1) CH698144B1 (ru)
EA (1) EA010240B1 (ru)
FR (1) FR2859910B1 (ru)
NL (1) NL1027109C2 (ru)
NZ (1) NZ535531A (ru)
WO (1) WO2005027923A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
SI1806136T1 (sl) * 2004-10-06 2012-03-30 Kissei Pharmaceutical Medicinski sestavek za preprečevanje prehoda na operativno zdravljenje prostatične hipertrofije
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906B1 (fr) * 2017-03-20 2025-12-12 Pf Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
CN120960385A (zh) * 2025-08-01 2025-11-18 上海交通大学医学院附属第九人民医院 5α–还原酶降解分子及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
AU743514B2 (en) * 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物

Also Published As

Publication number Publication date
HK1085373A1 (zh) 2006-08-25
FR2859910A1 (fr) 2005-03-25
CH698144B1 (fr) 2009-05-29
CN100488511C (zh) 2009-05-20
BRPI0404050A (pt) 2005-06-14
FR2859910B1 (fr) 2006-04-28
CN1615891A (zh) 2005-05-18
BE1016292A3 (nl) 2006-07-04
NL1027109A1 (nl) 2005-03-29
JP2009035559A (ja) 2009-02-19
EA010240B1 (ru) 2008-06-30
WO2005027923A1 (en) 2005-03-31
JP2007506699A (ja) 2007-03-22
EP1673096A1 (en) 2006-06-28
NL1027109C2 (nl) 2005-05-03
NZ535531A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
CL2007002953A1 (es) Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
UY27711A1 (es) Compuestos útiles en terapia
BRPI0307699A2 (pt) Tratamento de hiperplasia benigna da próstata com sarms.
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
CY1107674T1 (el) Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
NO20053783D0 (no) Behandling av godartet prostatahyperplasi
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
WO2008046082A3 (en) Use of heterocyclic compounds as therapeutic agents
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
EP1781277A4 (en) COMBINATION PREPARATION
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
UA56965U (ru) Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и paka предстательной железы
WO2004089379A3 (en) Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
GB0301016D0 (en) Treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU